Is UNII-J4T82NDH7E Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-J4T82NDH7E? Is UNII-J4T82NDH7E safe for nursing mother and child? Does UNII-J4T82NDH7E extracts into breast milk? Does UNII-J4T82NDH7E has any long term or short term side effects on infants? Can UNII-J4T82NDH7E influence milk supply or can UNII-J4T82NDH7E decrease milk supply in lactating mothers?

• DrLact safety Score for UNII-J4T82NDH7E is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of UNII-J4T82NDH7E may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that UNII-J4T82NDH7E may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using UNII-J4T82NDH7E .
• It is recommended to evaluate the advantage of not breastfeeding while using UNII-J4T82NDH7E Vs not using UNII-J4T82NDH7E And continue breastfeeding.
• While using UNII-J4T82NDH7E Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Inhibitor of Epidermal Growth Factor receptor that acts by inhibition of tyrosine kinase phosphorylation and used for treatment of several types of cancer. At latest update, relevant published data on excretion into breast milk were not found. Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely. If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, breastfeeding should be stopped for 10 half-lives (T ½). It means wait 15 days after the last dose before resuming breastfeeding. Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.

No information is available on the clinical use of UNII-J4T82NDH7E during breastfeeding. Because UNII-J4T82NDH7E is 93% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 36 hours and it might accumulate in the infant. It is also given in combination with gemcitabine for pancreatic cancer, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during UNII-J4T82NDH7E therapy and for 2 weeks after the final dose.